<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Oncol Lett</journal-id><journal-id journal-id-type="iso-abbrev">Oncol Lett</journal-id><journal-id journal-id-type="publisher-id">OL</journal-id><journal-title-group><journal-title>Oncology Letters</journal-title></journal-title-group><issn pub-type="ppub">1792-1074</issn><issn pub-type="epub">1792-1082</issn><publisher><publisher-name>D.A. Spandidos</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28943965</article-id><article-id pub-id-type="pmc">5594253</article-id><article-id pub-id-type="doi">10.3892/ol.2017.6732</article-id><article-id pub-id-type="publisher-id">OL-0-0-6732</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group></article-categories><title-group><article-title>Dosimetric comparison and observation of three-dimensional conformal radiotherapy for recurrent nasopharyngeal carcinoma</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Pan</surname><given-names>Rongqiang</given-names></name><xref ref-type="aff" rid="af1-ol-0-0-6732">1</xref></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Jingming</given-names></name><xref ref-type="aff" rid="af2-ol-0-0-6732">2</xref><xref rid="c1-ol-0-0-6732" ref-type="corresp"/></contrib><contrib contrib-type="author"><name><surname>Qi</surname><given-names>Feng</given-names></name><xref ref-type="aff" rid="af3-ol-0-0-6732">3</xref></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Ruizhen</given-names></name><xref ref-type="aff" rid="af3-ol-0-0-6732">3</xref></contrib></contrib-group><aff id="af1-ol-0-0-6732"><label>1</label>Cancer Center, Nanchong Central Hospital, Nanchong, Sichuan 637000, P.R. China</aff><aff id="af2-ol-0-0-6732"><label>2</label>Department of Ear, Nose and Throat, Gansu Provincial Maternity and Child Care Hospital, Lanzhou, Gansu 730050, P.R. China</aff><aff id="af3-ol-0-0-6732"><label>3</label>Department of Radiotherapy, The First People's Hospital of Shangqiu, Shangqiu, Henan 476100, P.R. China</aff><author-notes><corresp id="c1-ol-0-0-6732"><italic>Correspondence to</italic>: Dr Jingming Wang, Department of Ear, Nose and Throat, Gansu Provincial Maternity and Child Care Hospital, 143 Qilihe North Street, Lanzhou, Gansu 730050, P.R. China, E-mail: <email>wangjingming17@163.com</email></corresp></author-notes><pub-date pub-type="ppub"><month>10</month><year>2017</year></pub-date><pub-date pub-type="epub"><day>08</day><month>8</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>08</day><month>8</month><year>2017</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. --><volume>14</volume><issue>4</issue><fpage>4741</fpage><lpage>4745</lpage><history><date date-type="received"><day>14</day><month>3</month><year>2017</year></date><date date-type="accepted"><day>21</day><month>6</month><year>2017</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; Pan et al.</copyright-statement><copyright-year>2017</copyright-year><license license-type="open-access"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution-NonCommercial-NoDerivs License</ext-link>, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.</license-p></license></permissions><abstract><p>The aim of the study was to investigate the effect of three-dimensional conformal radiation therapy (3D-CRT) on nasopharyngeal carcinoma (NPC) and the incidence of complications. Between May 2010 and June 2012, 141 patients diagnosed with local recurrence of NPC due to cranial base lesions or cranial nerve symptoms, confirmed by pathology biopsy and/or by CT/MRI, were included in the present study. In accordance with the principle of randomized control, the patients were divided into three groups and treated with three different doses of 3D-CRT. The planned radiotherapy doses of 3D-CRT were 58/1.8&#x02013;2 Gy, 62/1.8&#x02013;2 Gy and 68/1.8&#x02013;2 Gy, respectively. The survival rate, disease-free survival (DFS) rate and local control rate of the three groups of patients were compared as well as the adverse reactions observed after radiotherapy. The prognoses of NPC patients were analyzed by univariate and multivariate analyses. The follow-up rate of the study was 100%. The 5-year overall survival, DFS, and locoregional recurrence-free survival rates were: 43.2 vs. 64.53 vs. 75%, 29.13 vs. 42.82 vs. 39.7% and 30.76 vs. 44.19 vs. 45.4%, respectively. In addition, 62/1.8&#x02013;2 Gy was similar in treatment effects to 68/1.8&#x02013;2 Gy, but 68/1.8&#x02013;2 Gy showed more adverse reactions than 62/1.8&#x02013;2 Gy. Thus, 62/1.8&#x02013;2 Gy can be used as a safe and effective dose for 3D-CRT treatment of NPC. Univariate and multivariate analyses showed that age may be the main prognostic factor of patients with NPC. In conclusion, 3D-CRT with a dose of 62/1.8&#x02013;2 Gy is a safe, effective and tolerable treatment for NPC patients with good clinical value.</p></abstract><kwd-group><kwd>nasopharyngeal carcinoma</kwd><kwd>local recurrence</kwd><kwd>re-irradiation</kwd><kwd>3D-CRT</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Nasopharyngeal carcinoma (NPC) is a common head and neck cancer. Owing to its sensitivity to radiation, radiotherapy is the most important method used to treat NPC (<xref rid="b1-ol-0-0-6732" ref-type="bibr">1</xref>,<xref rid="b2-ol-0-0-6732" ref-type="bibr">2</xref>). Since the site where NPC occurs usually has limited space and the head and facial nerve distribution is widespread, there are only limited treatments for NPC.</p><p>Commonly used methods of treatment include surgery, posterior implantation or implantation of radiation therapy as well as stereotactic radiotherapy and external irradiation (<xref rid="b3-ol-0-0-6732" ref-type="bibr">3</xref>&#x02013;<xref rid="b5-ol-0-0-6732" ref-type="bibr">5</xref>). Due to the wide spread of nasopharyngeal mass, surgery, endovascular grafting, implantation of radiotherapy and stereotactic radiotherapy are often limited, which causes a high recurrence of NPC. High-dose external irradiation is the main treatment for patients with relapse, especially for those with large local masses or a wide range attack when recurrence occurs (<xref rid="b6-ol-0-0-6732" ref-type="bibr">6</xref>,<xref rid="b7-ol-0-0-6732" ref-type="bibr">7</xref>). As conventional radiotherapy can often lead to serious complications and sequelae, including nasopharyngeal ulcers, hearing loss, temporal lobe necrosis, radiation encephalopathy, posterior cranial nerve injury and/or difficulty in mouth opening (<xref rid="b7-ol-0-0-6732" ref-type="bibr">7</xref>), in recent years we have continued to explore new radiotherapy treatments that can reduce the incidence of adverse reactions.</p><p>Three-dimensional conformal radiation therapy (3D-CRT) is an advanced treatment technique that can irradiate the target area through multiple fields (usually 5&#x02013;7 fields) to align the tumor with the radiation target through three-dimensional directions. It makes the target dose distribution more reasonable and reduces exposure to adjacent normal tissue (<xref rid="b8-ol-0-0-6732" ref-type="bibr">8</xref>). To the best of our knowlegde, few studies have focused on the treatment of recurrent NPC by 3D-CRT. Therefore, the aim of the present study is to analyze the efficacy of 3D-CRT in the treatment of recurrent NPC and long-term adverse effects after radiotherapy.</p></sec><sec sec-type="materials|methods"><title>Materials and methods</title><sec><title/><sec><title>Materials</title><p>Between May 2010 and June 2012, 141 patients with NPC who had been diagnosed with local recurrence by biopsy and/or computed tomography/magnetic resonance imaging (CT/MRI) imaging of bone destruction or cranial nerve symptom progression received 3D-CRT treatment. The median relapse interval was 27.5 months (range, 3&#x02013;156 months). Chest X-ray, abdominal B-ultrasound, head and neck CT/MRI, electrocardiogram, bone scan and oral, and other tests were performed. Since July 2005, CT was replaced with MRI in the head and neck exam (CT before July and MRI after July). PET/CT examination was performed based on the physician's judgement depending on the condition of the patient. No neck biopsy was performed in 10 patients with recurrence in neck. All the patients were re-staged according to the AJCC (5th edition, 1997).</p><p>Signed written informed consent was obtained from patients enrolled in the study. The study was approved by the Ethics Committee of the Nanchong Central Hospital (Nanchong, China).</p></sec><sec><title>3D-CRT radiotherapy treatment plan</title><p>The patients were placed in a supine position and wore a thermoplastic mask. CT was performed from the head to 2 cm below the clavicle, with a scanning layer of 3 mm and an enhanced scan. From July 2005 onwards, the MRI/CT image was produced using MasterPlan<sup>&#x000ae;</sup> version 1.5, Nucletron BV software analysis and image fusion.</p><p>Gross tumor volume (GTV), such as GTV-P (planned target area of primary tumor area) and GTV-N (unplanned target area of primary tumor area), including masses visible on CT/MRI images as well as clinical target volume (CTV), including CTV-P and CTV-N received external radiation of 8&#x02013;10 mm. If the mass was close to the brain stem or spinal cord, the exposure of the radiation boundary was smaller, with the smallest distance being 3 mm, to protect the brain stem and spinal cord from receiving more than the allowable tolerated dose. Cervical lymphatic drainage area did not receive prophylactic irradiation. Considering the system and positioning errors, 3 mm beyond CTV was considered as planning target volume (PTV). Organs affected included brain stem, spinal cord, optic nerve, optic chiasm, temporal lobe, pituitary, temporomandibular joint, eyeball, crystal and parotid gland. The dose received by affected organs was limited and individualized based on the first dose of radiotherapy, but within the tolerances specified by RTOG.</p><p>The treatment plan involved Plato<sup>&#x000ae;</sup> preparation planning software system (RTS<sup>&#x000ae;</sup> version 2.6.4), using isocentric coplanar or non-coplanar techniques; the isocenter is placed at the center of GTV-P. The irradiation of primary focus and neck involved 5&#x02013;9 coplanar static intensity control technology. The prescribed doses were PTV-GTVnx, 70 Gy; PTV-GTVnd, 64&#x02013;66 Gy; PTV-GTVnd, 64&#x02013;66 Gy; PTV-CTVnx60, 60&#x02013;64 Gy; PTV-CTVx50, 54 Gy; and PTV-CTVnd, 54 Gy; 31&#x02013;32 times of segmentation irradiation. The mean radiotherapy dose of 3D-CRT for three groups of patients were 58/1.8&#x02013;2 Gy, 62/1.8&#x02013;2 Gy and 68/1.8&#x02013;2 Gy respectively (single segmentation 2/1.8 Gy, once a day, 5 days/week). Five to seven coplanar irradiation fields were designed and a medical accelerator and a multi-leaf grating were used.</p></sec><sec><title>Radiotherapy</title><p>Due to the absence of current standard chemotherapy regimens for local recurrence of NPC, clinicians can consider whether to prescribe a combined chemotherapy based on the overall state of health of patients. In our study, 65 patients received 2&#x02013;6 cycles of platinum-based monotherapy or combinations of chemotherapy with neoadjuvant and/or concurrent adjuvant chemotherapy.</p></sec><sec><title>Follow-up</title><p>Patients were enrolled in a weekly check up for clinicians to evaluate the retraction of their lumps. Patients administered chemotherapy received routine blood, liver and kidney tests weekly. The patients were followed up every 3 months within 2 years after the treatment, every 6 months 3 years after the treatment and every year 5 years after the treatment. Each follow up included systemic examination, blood, VCA-IgA, VCA-EA, nose pharyngeal fibrobronchoscopy, chest X-ray, abdominal B-ultrasound, and head and neck MRI. Adverse reactions and sequelae were recorded according to the RTOG/EORTC assessment of adverse reactions of radiation therapy.</p></sec><sec><title>Statistical analysis</title><p>SPSS 19.0 software (IBM, Armonk, NY, USA) was used for statistical analysis. The time at which a local region relapses or shifts was calculated from the end of the 3D-CRT. Overall survival (OS) was defined as the time between the diagnosis of relapse and death or the last follow up. Locoregional recurrence-free survival (LRRFS), disease-free survival (DFS) and OS were calculated using the Kaplan-Meier method. The log-rank test was used for univariate analysis of different prognostic factors. The Cox regression model was used for multivariate analysis. P&#x0003c;0.05 was considered to indicate a statistically significant difference.</p></sec></sec></sec><sec sec-type="results"><title>Results</title><sec><title/><sec><title>Comparison of the general clinical situation of patients enrolled</title><p>The general clinical conditions of the patients were compared, including age, sex, T stage, whether to receive chemotherapy, time of recurrence and tumor invasion. The patient's age ranged from 26 to 71 years with an average age of 45 years. There was no statistically significant difference between the three groups in general clinical baseline data (P&#x0003e;0.05) (<xref rid="tI-ol-0-0-6732" ref-type="table">Table I</xref>).</p></sec><sec><title>Survival prognosis</title><p>The prognosis of the three groups of patients were analyzed. The OS, DFS and LRRFS of the 3 groups of patients were: 43.2 vs. 64.53 vs. 75%, 29.13 vs. 42.82 vs. 39.7%, 30.76 vs. 44.19 vs. 45.4%, respectively (<xref rid="f1-ol-0-0-6732" ref-type="fig">Fig. 1</xref>).</p></sec><sec><title>Comparison of the incidence of adverse reactions</title><p>Adverse reactions mainly included nasopharyngeal ulcer, cranial nerve injury, mouth opening difficulties and hearing loss. The overall adverse reaction rate of the 68/1.8&#x02013;2 Gy group was higher than that of the other two groups and the difference was statistically significant (P&#x0003c;0.05) (<xref rid="tII-ol-0-0-6732" ref-type="table">Table II</xref>).</p></sec><sec><title>Univariate prognostic analysis</title><p>The prognostic factors of the patients were analyzed by a univariate analysis. The prognostic factors included sex, age, treatment regimen (with or without chemotherapy), total radiation dose, primary T stage, recurrence T stage and recurrence interval. The results showed that age &#x02265;50 years of age was a risk factor for poor prognosis (<xref rid="tIII-ol-0-0-6732" ref-type="table">Tables III</xref> and <xref rid="tIV-ol-0-0-6732" ref-type="table">IV</xref>).</p></sec></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>Nasopharyngeal carcinoma, after a timely and standardized radical radiotherapy or integrated radiotherapy and chemotherapy, can lead to local and/or regional recurrence in 20&#x02013;30% of patients. Local nasopharyngeal and skull-based recurrence are the main reasons for the failure of local treatment of NPC after radiotherapy (<xref rid="b9-ol-0-0-6732" ref-type="bibr">9</xref>&#x02013;<xref rid="b11-ol-0-0-6732" ref-type="bibr">11</xref>). Retrospective studies have shown that salvage therapy can improve survival in patients with a single local recurrence (especially those with local recurrence of T1-2) (<xref rid="b12-ol-0-0-6732" ref-type="bibr">12</xref>). For nasopharyngeal local recurrence of T1-2, surgery or follow-up treatment is an effective means of NPC (<xref rid="b13-ol-0-0-6732" ref-type="bibr">13</xref>). Some radiotherapy centers reported treatment results showing that intraluminal or interstitial brachytherapy was also feasible for patients with local recurrence of NPC (<xref rid="b14-ol-0-0-6732" ref-type="bibr">14</xref>,<xref rid="b15-ol-0-0-6732" ref-type="bibr">15</xref>). Accordingly, Law <italic>et al</italic> (<xref rid="b16-ol-0-0-6732" ref-type="bibr">16</xref>) showed that, the use of <sup>192</sup>Ir interstitial particles DT50-55 Gy could lead to a 5-year local control rate of 85% and moderate as well as severe complications occurrence rate of 47%. Leung <italic>et al</italic> used high-dose rate of intracavitary and external irradiation treatment for recurrent NPC (<xref rid="b17-ol-0-0-6732" ref-type="bibr">17</xref>). The results showed that although the high dose of radiation was strong enough to kill local cancer cells, it could also cause local early recurrence due to normal tissue damage and interstitial cell damage.</p><p>In the present study, the patients with NPC were treated with different doses of radiation ranging from 58 to 68 Gy. The results showed that the three groups of patients had 5-year OS, DFS and regional recurrence-free survival rates as 43.2 vs. 64.53 vs. 75%, 29.13 vs. 42.82 vs. 39.7% and 30.76 vs. 44.19 vs. 45.4%. The treatment effect of 62/1.8&#x02013;2 Gy was similar to that of 68/1.8&#x02013;2 Gy, but 68/1.8&#x02013;2 Gy showed more adverse reactions than 62/1.8&#x02013;2 Gy. Therefore, we believe that 62/1.8&#x02013;2 Gy can be used as a safe and effective dose for 3D-CRT treatment of NPC. Age may be the main prognostic risk factor for patients with NPC (<xref rid="b18-ol-0-0-6732" ref-type="bibr">18</xref>). Previous findings have shown that radiation dose in the treatment of cancer may be positively correlated with an increase in side effects. Chang <italic>et al</italic> treated 35 patients with recurrent NPC using 3D-CRT (<xref rid="b19-ol-0-0-6732" ref-type="bibr">19</xref>). The results showed that the median survival rates of radiotherapy after 1, 2 and 3 years were 54.9, 30.2 and 22.9%, respectively. Additionaly, long-term adverse reactions included hearing loss and difficulty in mouth opening compared to the conventional group, albeit no brain necrosis was found. Our study further explored the dose and safety of three-dimensional radiotherapy, and further determined 62/1.8&#x02013;2 Gy as a therapeutic dose with certain clinical applicability. Teo <italic>et al</italic> reported that more than 900 patients with recurrences showed better therapeutic effects when the radiation dose was &#x02265;60 Gy (<xref rid="b20-ol-0-0-6732" ref-type="bibr">20</xref>). Those authors, however, did not explore in-depth the radiation dose &#x02265;60 Gy, and the DFS and OS rates of patients. In this study, the 62 and 68 Gy radiation doses were further categorized and explored because of differences in the patient population and the number of patients enrolled in the study. We found that 62/1.8&#x02013;2 Gy was safer and more effective as a three-dimensional radiotherapy dose and could lead to longer OS and DFS.</p><p>In conclusion, we believe that the dose of 62/1.8&#x02013;2 Gy of 3D-CRT is a safe, effective and adverse-reaction-tolerable NPC treatment with good clinical values.</p></sec></body><back><ref-list><title>References</title><ref id="b1-ol-0-0-6732"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lv</surname><given-names>X</given-names></name><name><surname>Xia</surname><given-names>WX</given-names></name><name><surname>Ke</surname><given-names>LR</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Qiu</surname><given-names>WZ</given-names></name><name><surname>Yu</surname><given-names>YH</given-names></name><name><surname>Liang</surname><given-names>H</given-names></name><name><surname>Huang</surname><given-names>XJ</given-names></name><name><surname>Liu</surname><given-names>GY</given-names></name><name><surname>Zeng</surname><given-names>Q</given-names></name><etal/></person-group><article-title>Comparison of the short-term efficacy between docetaxel plus carboplatin and 5-fluorouracil plus carboplatin in locoregionally advanced nasopharyngeal carcinoma</article-title><source>Onco Targets Ther</source><volume>9</volume><fpage>5123</fpage><lpage>5131</lpage><year>2016</year><pub-id pub-id-type="doi">10.2147/OTT.S103729</pub-id><pub-id pub-id-type="pmid">27574453</pub-id></element-citation></ref><ref id="b2-ol-0-0-6732"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeng</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Lv</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Yin</surname><given-names>LJ</given-names></name><name><surname>Xiang</surname><given-names>YQ</given-names></name><name><surname>Guo</surname><given-names>X</given-names></name></person-group><article-title>Induction chemotherapy followed by radiotherapy versus concurrent chemoradiotherapy in elderly patients with nasopharyngeal carcinoma: Finding from a propensity-matched analysis</article-title><source>BMC Cancer</source><volume>16</volume><fpage>693</fpage><year>2016</year><pub-id pub-id-type="doi">10.1186/s12885-016-2661-y</pub-id><pub-id pub-id-type="pmid">27577729</pub-id></element-citation></ref><ref id="b3-ol-0-0-6732"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ho</surname><given-names>S</given-names></name><name><surname>Ip</surname><given-names>W</given-names></name><name><surname>Chu</surname><given-names>S</given-names></name><name><surname>Chan</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>B</given-names></name><name><surname>Chan</surname><given-names>B</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Flynn</surname><given-names>B</given-names></name><name><surname>Ho</surname><given-names>W</given-names></name><name><surname>Sin</surname><given-names>J</given-names></name><etal/></person-group><article-title>Treatment regret in long-term survivors of nasopharyngeal carcinoma treated with radical radiotherapy</article-title><source>Clin Oncol (R Coll Radiol)</source><volume>29</volume><fpage>e47</fpage><year>2017</year><pub-id pub-id-type="doi">10.1016/j.clon.2016.08.006</pub-id><pub-id pub-id-type="pmid">27567302</pub-id></element-citation></ref><ref id="b4-ol-0-0-6732"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>C</given-names></name><name><surname>Luo</surname><given-names>J</given-names></name><name><surname>Gao</surname><given-names>L</given-names></name><name><surname>Yi</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Xiao</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Xu</surname><given-names>G</given-names></name></person-group><article-title>Magnetic resonance imaging-detected intracranial extension in the T4 classification nasopharyngeal carcinoma with intensity-modulated radiotherapy</article-title><source>Cancer Res Treat</source><volume>49</volume><fpage>518</fpage><lpage>525</lpage><year>2017</year><pub-id pub-id-type="doi">10.4143/crt.2016.299</pub-id><pub-id pub-id-type="pmid">27554478</pub-id></element-citation></ref><ref id="b5-ol-0-0-6732"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Zhao</surname><given-names>C</given-names></name><name><surname>Xue</surname><given-names>W</given-names></name><name><surname>Han</surname><given-names>F</given-names></name><name><surname>Tao</surname><given-names>T</given-names></name><name><surname>Chang</surname><given-names>H</given-names></name><name><surname>Jia</surname><given-names>W</given-names></name><name><surname>Lu</surname><given-names>T</given-names></name></person-group><article-title>Prognostic efficacy of combining tumor volume with Epstein-Barr virus DNA in patients treated with intensity-modulated radiotherapy for nasopharyngeal carcinoma</article-title><source>Oral Oncol</source><volume>60</volume><fpage>18</fpage><lpage>24</lpage><year>2016</year><pub-id pub-id-type="doi">10.1016/j.oraloncology.2016.06.013</pub-id><pub-id pub-id-type="pmid">27531868</pub-id></element-citation></ref><ref id="b6-ol-0-0-6732"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maingon</surname><given-names>P</given-names></name><name><surname>Blanchard</surname><given-names>P</given-names></name><name><surname>Bidault</surname><given-names>F</given-names></name><name><surname>Calmels</surname><given-names>L</given-names></name></person-group><article-title>Radiotherapy for nasopharyngeal carcinoma</article-title><source>Cancer Radiother</source><volume>20</volume><fpage>S104</fpage><lpage>S109</lpage><year>2016</year><comment>(In French)</comment><pub-id pub-id-type="doi">10.1016/j.canrad.2016.07.031</pub-id><pub-id pub-id-type="pmid">27523419</pub-id></element-citation></ref><ref id="b7-ol-0-0-6732"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Li</surname><given-names>YH</given-names></name><name><surname>Fu</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name></person-group><article-title>Diffusion kurtosis imaging study on temporal lobe after nasopharyngeal carcinoma radiotherapy</article-title><source>Brain Res</source><volume>1648</volume><fpage>387</fpage><lpage>393</lpage><year>2016</year><pub-id pub-id-type="doi">10.1016/j.brainres.2016.07.041</pub-id><pub-id pub-id-type="pmid">27514570</pub-id></element-citation></ref><ref id="b8-ol-0-0-6732"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakahara</surname><given-names>S</given-names></name><name><surname>Hanamoto</surname><given-names>A</given-names></name><name><surname>Seo</surname><given-names>Y</given-names></name><name><surname>Miyaguchi</surname><given-names>S</given-names></name><name><surname>Yamamoto</surname><given-names>Y</given-names></name><name><surname>Tomiyama</surname><given-names>Y</given-names></name><name><surname>Yoshii</surname><given-names>T</given-names></name><name><surname>Takenaka</surname><given-names>Y</given-names></name><name><surname>Yoshioka</surname><given-names>Y</given-names></name><name><surname>Isohashi</surname><given-names>F</given-names></name><etal/></person-group><article-title>Chemoradiotherapy with weekly low-dose docetaxel and cisplatin concurrent with radiation for patients with locally advanced nasopharyngeal carcinoma, followed by adjuvant chemotherapy for selected patients</article-title><source>Jpn J Clin Oncol</source><volume>46</volume><fpage>903</fpage><lpage>910</lpage><year>2016</year><pub-id pub-id-type="doi">10.1093/jjco/hyw100</pub-id><pub-id pub-id-type="pmid">27474126</pub-id></element-citation></ref><ref id="b9-ol-0-0-6732"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>Q</given-names></name><name><surname>Wu</surname><given-names>D</given-names></name><name><surname>Zeng</surname><given-names>LL</given-names></name><name><surname>Shen</surname><given-names>H</given-names></name><name><surname>Hu</surname><given-names>D</given-names></name><name><surname>Qiu</surname><given-names>S</given-names></name></person-group><article-title>Radiation-induced functional connectivity alterations in nasopharyngeal carcinoma patients with radiotherapy</article-title><source>Medicine (Baltimore)</source><volume>95</volume><fpage>e4275</fpage><year>2016</year><pub-id pub-id-type="doi">10.1097/MD.0000000000004275</pub-id><pub-id pub-id-type="pmid">27442663</pub-id></element-citation></ref><ref id="b10-ol-0-0-6732"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>E</given-names></name><name><surname>Owen</surname><given-names>R</given-names></name><name><surname>Harden</surname><given-names>F</given-names></name><name><surname>Mengersen</surname><given-names>K</given-names></name><name><surname>Oestreich</surname><given-names>K</given-names></name><name><surname>Houghton</surname><given-names>W</given-names></name><name><surname>Poulsen</surname><given-names>M</given-names></name><name><surname>Harris</surname><given-names>S</given-names></name><name><surname>Lin</surname><given-names>C</given-names></name><name><surname>Porceddu</surname><given-names>S</given-names></name></person-group><article-title>Head and neck adaptive radiotherapy: Predicting the time to replan</article-title><source>Asia Pac J Clin Oncol</source><volume>12</volume><fpage>460</fpage><lpage>467</lpage><year>2016</year><pub-id pub-id-type="doi">10.1111/ajco.12516</pub-id><pub-id pub-id-type="pmid">27435432</pub-id></element-citation></ref><ref id="b11-ol-0-0-6732"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>SX</given-names></name><name><surname>Chua</surname><given-names>DT</given-names></name><name><surname>Deng</surname><given-names>ML</given-names></name><name><surname>Zhao</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>FY</given-names></name><name><surname>Sham</surname><given-names>JS</given-names></name><name><surname>Wang</surname><given-names>HY</given-names></name><name><surname>Bao</surname><given-names>Y</given-names></name><name><surname>Gao</surname><given-names>YH</given-names></name><name><surname>Zeng</surname><given-names>ZF</given-names></name></person-group><article-title>Outcome of fractionated stereotactic radiotherapy for 90 patients with locally persistent and recurrent nasopharyngeal carcinoma</article-title><source>Int J Radiat Oncol Biol Phys</source><volume>69</volume><fpage>761</fpage><lpage>769</lpage><year>2007</year><pub-id pub-id-type="doi">10.1016/j.ijrobp.2007.03.037</pub-id><pub-id pub-id-type="pmid">17601682</pub-id></element-citation></ref><ref id="b12-ol-0-0-6732"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>FC</given-names></name><name><surname>Tung</surname><given-names>SY</given-names></name><name><surname>Leung</surname><given-names>TW</given-names></name><name><surname>Sze</surname><given-names>WK</given-names></name><name><surname>Wong</surname><given-names>VY</given-names></name><name><surname>Lui</surname><given-names>CM</given-names></name><name><surname>Yuen</surname><given-names>KK</given-names><suffix>OSK</suffix></name></person-group><article-title>Treatment results of high-dose-rate remote afterloading brachytherapy for cervical cancer and retrospective comparison of two regimens</article-title><source>Int J Radiat Oncol Biol Phys</source><volume>55</volume><fpage>1254</fpage><lpage>1264</lpage><year>2003</year><pub-id pub-id-type="doi">10.1016/S0360-3016(02)04525-X</pub-id><pub-id pub-id-type="pmid">12654435</pub-id></element-citation></ref><ref id="b13-ol-0-0-6732"><label>13</label><element-citation publication-type="book"><person-group person-group-type="editor"><name><surname>Lu</surname><given-names>J</given-names></name><name><surname>Cooper</surname><given-names>J</given-names></name><name><surname>Lee</surname><given-names>A</given-names></name></person-group><source>Nasopharyngeal Cancer: Multidisciplinary Management</source><publisher-name>Springer-Verlag</publisher-name><publisher-loc>Berlin, Heidelberg</publisher-loc><fpage>253</fpage><lpage>265</lpage><year>2010</year></element-citation></ref><ref id="b14-ol-0-0-6732"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fee</surname><given-names>WE</given-names><suffix>Jr</suffix></name><name><surname>Moir</surname><given-names>MS</given-names></name><name><surname>Choi</surname><given-names>EC</given-names></name><name><surname>Goffinet</surname><given-names>D</given-names></name></person-group><article-title>Nasopharyngectomy for recurrent nasopharyngeal cancer: A 2- to 17-year follow-up</article-title><source>Arch Otolaryngol Head Neck Surg</source><volume>128</volume><fpage>280</fpage><lpage>284</lpage><year>2002</year><pub-id pub-id-type="doi">10.1001/archotol.128.3.280</pub-id><pub-id pub-id-type="pmid">11886344</pub-id></element-citation></ref><ref id="b15-ol-0-0-6732"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>W</given-names></name></person-group><article-title>Cancer of the nasopharynx: Functional surgical salvage</article-title><source>World J Surg</source><volume>27</volume><fpage>844</fpage><lpage>848</lpage><year>2003</year><pub-id pub-id-type="doi">10.1007/s00268-003-7110-9</pub-id><pub-id pub-id-type="pmid">14509517</pub-id></element-citation></ref><ref id="b16-ol-0-0-6732"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Law</surname><given-names>SC</given-names></name><name><surname>Lam</surname><given-names>WK</given-names></name><name><surname>Ng</surname><given-names>MF</given-names></name><name><surname>Au</surname><given-names>SK</given-names></name><name><surname>Mak</surname><given-names>WT</given-names></name><name><surname>Lau</surname><given-names>WH</given-names></name></person-group><article-title>Reirradiation of nasopharyngeal carcinoma with intracavitary mold brachytherapy: An effective means of local salvage</article-title><source>Int J Radiat Oncol Biol Phys</source><volume>54</volume><fpage>1095</fpage><lpage>1113</lpage><year>2002</year><pub-id pub-id-type="doi">10.1016/S0360-3016(02)03009-2</pub-id><pub-id pub-id-type="pmid">12419437</pub-id></element-citation></ref><ref id="b17-ol-0-0-6732"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leung</surname><given-names>TW</given-names></name><name><surname>Tung</surname><given-names>SY</given-names></name><name><surname>Sze</surname><given-names>WK</given-names></name><name><surname>Sze</surname><given-names>WM</given-names></name><name><surname>Wong</surname><given-names>VY</given-names></name><name><surname>Wong</surname><given-names>CS</given-names><suffix>OSK</suffix></name></person-group><article-title>Salvage radiation therapy for locally recurrent nasopharyngeal carcinoma</article-title><source>Int J Radiat Oncol Biol Phys</source><volume>48</volume><fpage>1331</fpage><lpage>1338</lpage><year>2000</year><pub-id pub-id-type="doi">10.1016/S0360-3016(00)00776-8</pub-id><pub-id pub-id-type="pmid">11121630</pub-id></element-citation></ref><ref id="b18-ol-0-0-6732"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Mo</surname><given-names>Z</given-names></name><name><surname>Du</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Wei</surname><given-names>Y</given-names></name></person-group><article-title>Intensity-modulated radiation therapy versus 2D-RT or 3D-CRT for the treatment of nasopharyngeal carcinoma: A systematic review and meta-analysis</article-title><source>Oral Oncol</source><volume>51</volume><fpage>1041</fpage><lpage>1046</lpage><year>2015</year><pub-id pub-id-type="doi">10.1016/j.oraloncology.2015.08.005</pub-id><pub-id pub-id-type="pmid">26296274</pub-id></element-citation></ref><ref id="b19-ol-0-0-6732"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>JT</given-names></name><name><surname>See</surname><given-names>LC</given-names></name><name><surname>Liao</surname><given-names>CT</given-names></name><name><surname>Ng</surname><given-names>SH</given-names></name><name><surname>Wang</surname><given-names>CH</given-names></name><name><surname>Chen</surname><given-names>IH</given-names></name><name><surname>Tsang</surname><given-names>NM</given-names></name><name><surname>Tseng</surname><given-names>CK</given-names></name><name><surname>Tang</surname><given-names>SG</given-names></name><name><surname>Hong</surname><given-names>JH</given-names></name></person-group><article-title>Locally recurrent nasopharyngeal carcinoma</article-title><source>Radiother Oncol</source><volume>54</volume><fpage>135</fpage><lpage>142</lpage><year>2000</year><pub-id pub-id-type="doi">10.1016/S0167-8140(99)00177-2</pub-id><pub-id pub-id-type="pmid">10699476</pub-id></element-citation></ref><ref id="b20-ol-0-0-6732"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Teo</surname><given-names>PM</given-names></name><name><surname>Kwan</surname><given-names>WH</given-names></name><name><surname>Chan</surname><given-names>AT</given-names></name><name><surname>Lee</surname><given-names>WY</given-names></name><name><surname>King</surname><given-names>WW</given-names></name><name><surname>Mok</surname><given-names>CO</given-names></name></person-group><article-title>How successful is high-dose (&#x0003e; or = 60 Gy) reirradiation using mainly external beams in salvaging local failures of nasopharyngeal carcinoma?</article-title><source>Int J Radiat Oncol Biol Phys</source><volume>40</volume><fpage>897</fpage><lpage>913</lpage><year>1998</year><pub-id pub-id-type="doi">10.1016/S0360-3016(97)00854-7</pub-id><pub-id pub-id-type="pmid">9531376</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="f1-ol-0-0-6732" orientation="portrait" position="float"><label>Figure 1.</label><caption><p>Kaplan-Meier survival analysis. OS, overall survival; DFS, disease-free survival; LRRFS, locoregional recurrence-free survival.</p></caption><graphic xlink:href="ol-14-04-4741-g00"/></fig><table-wrap id="tI-ol-0-0-6732" orientation="portrait" position="float"><label>Table I.</label><caption><p>Comparison of the general clinical situation of patients enrolled.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/><th align="center" valign="bottom" colspan="3" rowspan="1">Groups</th><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/></tr><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/><th align="center" valign="bottom" colspan="3" rowspan="1"><hr/></th><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/></tr><tr><th align="left" valign="bottom" rowspan="1" colspan="1">Factors</th><th align="center" valign="bottom" rowspan="1" colspan="1">No.</th><th align="center" valign="bottom" rowspan="1" colspan="1">58/1.8&#x02013;2 Gy n=47</th><th align="center" valign="bottom" rowspan="1" colspan="1">62/1.8&#x02013;2 Gy n=47</th><th align="center" valign="bottom" rowspan="1" colspan="1">68/1.8&#x02013;2 Gy n=47</th><th align="center" valign="bottom" rowspan="1" colspan="1">&#x003c7;<sup>2</sup> value</th><th align="center" valign="bottom" rowspan="1" colspan="1">P-value</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Sex</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.473</td><td align="center" valign="top" rowspan="1" colspan="1">0.556</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x000a0;&#x000a0;Male</td><td align="center" valign="top" rowspan="1" colspan="1">70</td><td align="center" valign="top" rowspan="1" colspan="1">26</td><td align="center" valign="top" rowspan="1" colspan="1">24</td><td align="center" valign="top" rowspan="1" colspan="1">20</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x000a0;&#x000a0;Female</td><td align="center" valign="top" rowspan="1" colspan="1">71</td><td align="center" valign="top" rowspan="1" colspan="1">21</td><td align="center" valign="top" rowspan="1" colspan="1">23</td><td align="center" valign="top" rowspan="1" colspan="1">27</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Age (years)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.102</td><td align="center" valign="top" rowspan="1" colspan="1">0.732</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x02264;50</td><td align="center" valign="top" rowspan="1" colspan="1">68</td><td align="center" valign="top" rowspan="1" colspan="1">24</td><td align="center" valign="top" rowspan="1" colspan="1">21</td><td align="center" valign="top" rowspan="1" colspan="1">23</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x0003e;50</td><td align="center" valign="top" rowspan="1" colspan="1">73</td><td align="center" valign="top" rowspan="1" colspan="1">23</td><td align="center" valign="top" rowspan="1" colspan="1">26</td><td align="center" valign="top" rowspan="1" colspan="1">24</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">T stage</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.027</td><td align="center" valign="top" rowspan="1" colspan="1">0.973</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x000a0;&#x000a0;T1</td><td align="center" valign="top" rowspan="1" colspan="1">31</td><td align="center" valign="top" rowspan="1" colspan="1">13</td><td align="center" valign="top" rowspan="1" colspan="1">10</td><td align="center" valign="top" rowspan="1" colspan="1">&#x000a0;&#x000a0;8</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x000a0;&#x000a0;T2</td><td align="center" valign="top" rowspan="1" colspan="1">50</td><td align="center" valign="top" rowspan="1" colspan="1">14</td><td align="center" valign="top" rowspan="1" colspan="1">17</td><td align="center" valign="top" rowspan="1" colspan="1">19</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x000a0;&#x000a0;T3</td><td align="center" valign="top" rowspan="1" colspan="1">30</td><td align="center" valign="top" rowspan="1" colspan="1">&#x000a0;&#x000a0;9</td><td align="center" valign="top" rowspan="1" colspan="1">11</td><td align="center" valign="top" rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x000a0;&#x000a0;T4</td><td align="center" valign="top" rowspan="1" colspan="1">30</td><td align="center" valign="top" rowspan="1" colspan="1">11</td><td align="center" valign="top" rowspan="1" colspan="1">&#x000a0;&#x000a0;9</td><td align="center" valign="top" rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" colspan="7" rowspan="1">Combined chemotherapy</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x000a0;&#x000a0;No</td><td align="center" valign="top" rowspan="1" colspan="1">87</td><td align="center" valign="top" rowspan="1" colspan="1">27</td><td align="center" valign="top" rowspan="1" colspan="1">32</td><td align="center" valign="top" rowspan="1" colspan="1">28</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x000a0;&#x000a0;Yes</td><td align="center" valign="top" rowspan="1" colspan="1">54</td><td align="center" valign="top" rowspan="1" colspan="1">20</td><td align="center" valign="top" rowspan="1" colspan="1">15</td><td align="center" valign="top" rowspan="1" colspan="1">19</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Nasopharyngeal tumor</td><td align="center" valign="top" rowspan="1" colspan="1">55</td><td align="center" valign="top" rowspan="1" colspan="1">19</td><td align="center" valign="top" rowspan="1" colspan="1">22</td><td align="center" valign="top" rowspan="1" colspan="1">14</td><td align="center" valign="top" rowspan="1" colspan="1">0.483</td><td align="center" valign="top" rowspan="1" colspan="1">0.567</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">invasion to both sides</td><td align="center" valign="top" rowspan="1" colspan="1">86</td><td align="center" valign="top" rowspan="1" colspan="1">28</td><td align="center" valign="top" rowspan="1" colspan="1">25</td><td align="center" valign="top" rowspan="1" colspan="1">33</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Time of relapse</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.465</td><td align="center" valign="top" rowspan="1" colspan="1">0.587</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x0003c;24 months</td><td align="center" valign="top" rowspan="1" colspan="1">67</td><td align="center" valign="top" rowspan="1" colspan="1">17</td><td align="center" valign="top" rowspan="1" colspan="1">24</td><td align="center" valign="top" rowspan="1" colspan="1">26</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x000a0;&#x000a0;24-36 months</td><td align="center" valign="top" rowspan="1" colspan="1">28</td><td align="center" valign="top" rowspan="1" colspan="1">&#x000a0;&#x000a0;8</td><td align="center" valign="top" rowspan="1" colspan="1">&#x000a0;&#x000a0;9</td><td align="center" valign="top" rowspan="1" colspan="1">11</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x0003e;36 months</td><td align="center" valign="top" rowspan="1" colspan="1">46</td><td align="center" valign="top" rowspan="1" colspan="1">16</td><td align="center" valign="top" rowspan="1" colspan="1">17</td><td align="center" valign="top" rowspan="1" colspan="1">13</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr></tbody></table></table-wrap><table-wrap id="tII-ol-0-0-6732" orientation="portrait" position="float"><label>Table II.</label><caption><p>Comparison of adverse reaction rate.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom" rowspan="1" colspan="1">Groups</th><th align="center" valign="bottom" rowspan="1" colspan="1">Nasopharyngeal ulcer</th><th align="center" valign="bottom" rowspan="1" colspan="1">Cranial nerve injury</th><th align="center" valign="bottom" rowspan="1" colspan="1">Mouth opening difficulties</th><th align="center" valign="bottom" rowspan="1" colspan="1">Hearing loss</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">58/1.8&#x02013;2 Gy</td><td align="center" valign="top" rowspan="1" colspan="1">&#x000a0;&#x000a0;2</td><td align="center" valign="top" rowspan="1" colspan="1">&#x000a0;&#x000a0;1</td><td align="center" valign="top" rowspan="1" colspan="1">3</td><td align="center" valign="top" rowspan="1" colspan="1">2</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">62/1.8&#x02013;2 Gy</td><td align="center" valign="top" rowspan="1" colspan="1">&#x000a0;&#x000a0;0</td><td align="center" valign="top" rowspan="1" colspan="1">&#x000a0;&#x000a0;1</td><td align="center" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">4</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">68/1.8&#x02013;2 Gy</td><td align="center" valign="top" rowspan="1" colspan="1">15</td><td align="center" valign="top" rowspan="1" colspan="1">10</td><td align="center" valign="top" rowspan="1" colspan="1">3</td><td align="center" valign="top" rowspan="1" colspan="1">8</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x003c7;<sup>2</sup> value</td><td rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">32.8</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">P-value</td><td rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.001</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr></tbody></table></table-wrap><table-wrap id="tIII-ol-0-0-6732" orientation="portrait" position="float"><label>Table III.</label><caption><p>Univariate prognostic analysis.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/><th align="center" valign="bottom" colspan="2" rowspan="1">OS</th><th align="center" valign="bottom" colspan="2" rowspan="1">DFS</th><th align="center" valign="bottom" colspan="2" rowspan="1">LFS</th></tr><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/><th align="center" valign="bottom" colspan="2" rowspan="1"><hr/></th><th align="center" valign="bottom" colspan="2" rowspan="1"><hr/></th><th align="center" valign="bottom" colspan="2" rowspan="1"><hr/></th></tr><tr><th align="left" valign="bottom" rowspan="1" colspan="1">Factors</th><th align="center" valign="bottom" rowspan="1" colspan="1">n</th><th align="center" valign="bottom" rowspan="1" colspan="1">t</th><th align="center" valign="bottom" rowspan="1" colspan="1">P-value</th><th align="center" valign="bottom" rowspan="1" colspan="1">t</th><th align="center" valign="bottom" rowspan="1" colspan="1">P-value</th><th align="center" valign="bottom" rowspan="1" colspan="1">t</th><th align="center" valign="bottom" rowspan="1" colspan="1">P-value</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Sex</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.387</td><td rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.583</td><td rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.387</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x000a0;&#x000a0;Male</td><td align="center" valign="top" rowspan="1" colspan="1">70</td><td align="center" valign="top" rowspan="1" colspan="1">52.4&#x000b1;5.5</td><td rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">48.4&#x000b1;5.3</td><td rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">52.3&#x000b1;5.5</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x000a0;&#x000a0;Female</td><td align="center" valign="top" rowspan="1" colspan="1">71</td><td align="center" valign="top" rowspan="1" colspan="1">42.3&#x000b1;7.1</td><td rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">40.3&#x000b1;7.2</td><td rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">40.1&#x000b1;7.1</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Age (years)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.027</td><td rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.016</td><td rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.008</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x0003c;50</td><td align="center" valign="top" rowspan="1" colspan="1">68</td><td align="center" valign="top" rowspan="1" colspan="1">64.2&#x000b1;7.3</td><td rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">60.3&#x000b1;6.6</td><td rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">62.4&#x000b1;7.1</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x02265;50</td><td align="center" valign="top" rowspan="1" colspan="1">73</td><td align="center" valign="top" rowspan="1" colspan="1">55.4&#x000b1;7.2</td><td rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">38.7&#x000b1;4.5</td><td rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">38.6&#x000b1;5.2</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">rT stage</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.276</td><td rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.078</td><td rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.271</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x000a0;&#x000a0;1+2</td><td align="center" valign="top" rowspan="1" colspan="1">81</td><td align="center" valign="top" rowspan="1" colspan="1">57.3&#x000b1;7.2</td><td rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">58.7&#x000b1;7.2</td><td rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">57.5&#x000b1;8.2</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x000a0;&#x000a0;3+4</td><td align="center" valign="top" rowspan="1" colspan="1">60</td><td align="center" valign="top" rowspan="1" colspan="1">45.5&#x000b1;5.1</td><td rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">40.2&#x000b1;5.9</td><td rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">31.2&#x000b1;5.4</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Recurrence time</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.478</td><td rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.228</td><td rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.271</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x0003c;24 months</td><td align="center" valign="top" rowspan="1" colspan="1">67</td><td align="center" valign="top" rowspan="1" colspan="1">57.6&#x000b1;7.1</td><td rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">55.1&#x000b1;6.7</td><td rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">57.3&#x000b1;7.2</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x000a0;&#x000a0;24-36 months</td><td align="center" valign="top" rowspan="1" colspan="1">28</td><td align="center" valign="top" rowspan="1" colspan="1">43.6&#x000b1;7.2</td><td rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">41.2&#x000b1;6.6</td><td rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">43.4&#x000b1;7.7</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x0003e;36 months</td><td align="center" valign="top" rowspan="1" colspan="1">46</td><td align="center" valign="top" rowspan="1" colspan="1">44.9&#x000b1;8.1</td><td rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">39.7&#x000b1;7.1</td><td rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">41.7&#x000b1;7.2</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Radiation dose</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.323</td><td rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.227</td><td rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.863</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x0003c;60 Gy</td><td align="center" valign="top" rowspan="1" colspan="1">47</td><td align="center" valign="top" rowspan="1" colspan="1">47.3&#x000b1;5.5</td><td rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">57.2&#x000b1;9.1</td><td rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">49.3&#x000b1;5.5</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x000a0;&#x000a0;62 Gy</td><td align="center" valign="top" rowspan="1" colspan="1">47</td><td align="center" valign="top" rowspan="1" colspan="1">49.7&#x000b1;5.3</td><td rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">44.5&#x000b1;4.4</td><td rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">48.4&#x000b1;6.7</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x000a0;&#x000a0;68 Gy</td><td align="center" valign="top" rowspan="1" colspan="1">47</td><td align="center" valign="top" rowspan="1" colspan="1">48.3&#x000b1;4.3</td><td rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">46.5&#x000b1;4.3</td><td rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">48.1&#x000b1;5.3</td><td rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="tfn1-ol-0-0-6732"><p>OS, overall survival; DFS, disease-free survival.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tIV-ol-0-0-6732" orientation="portrait" position="float"><label>Table IV.</label><caption><p>Multivariate prognostic analysis.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/><th align="center" valign="bottom" colspan="2" rowspan="1">95% CI Exp (B)</th></tr><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/><th align="center" valign="bottom" colspan="2" rowspan="1"><hr/></th></tr><tr><th align="left" valign="bottom" rowspan="1" colspan="1">Factor</th><th align="center" valign="bottom" rowspan="1" colspan="1">B</th><th align="center" valign="bottom" rowspan="1" colspan="1">SE</th><th align="center" valign="bottom" rowspan="1" colspan="1">WALD</th><th align="center" valign="bottom" rowspan="1" colspan="1">df</th><th align="center" valign="bottom" rowspan="1" colspan="1">Sig</th><th align="center" valign="bottom" rowspan="1" colspan="1">Exp (B)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Lower</th><th align="center" valign="bottom" rowspan="1" colspan="1">Upper</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Age</td><td align="center" valign="top" rowspan="1" colspan="1">0.538</td><td align="center" valign="top" rowspan="1" colspan="1">0.215</td><td align="center" valign="top" rowspan="1" colspan="1">6.218</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">0.014</td><td align="center" valign="top" rowspan="1" colspan="1">1.701</td><td align="center" valign="top" rowspan="1" colspan="1">1.121</td><td align="center" valign="top" rowspan="1" colspan="1">2.598</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">T stage</td><td align="center" valign="top" rowspan="1" colspan="1">0.368</td><td align="center" valign="top" rowspan="1" colspan="1">0.206</td><td align="center" valign="top" rowspan="1" colspan="1">3.187</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">0.076</td><td align="center" valign="top" rowspan="1" colspan="1">1.453</td><td align="center" valign="top" rowspan="1" colspan="1">0.956</td><td align="center" valign="top" rowspan="1" colspan="1">2.156</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Age</td><td align="center" valign="top" rowspan="1" colspan="1">0.494</td><td align="center" valign="top" rowspan="1" colspan="1">0.207</td><td align="center" valign="top" rowspan="1" colspan="1">5.721</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">0.016</td><td align="center" valign="top" rowspan="1" colspan="1">1.635</td><td align="center" valign="top" rowspan="1" colspan="1">1.004</td><td align="center" valign="top" rowspan="1" colspan="1">2.448</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Age</td><td align="center" valign="top" rowspan="1" colspan="1">0.552</td><td align="center" valign="top" rowspan="1" colspan="1">0.212</td><td align="center" valign="top" rowspan="1" colspan="1">6.798</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">0.009</td><td align="center" valign="top" rowspan="1" colspan="1">1.747</td><td align="center" valign="top" rowspan="1" colspan="1">1.165</td><td align="center" valign="top" rowspan="1" colspan="1">2.628</td></tr></tbody></table></table-wrap></floats-group></article>